Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kevin Sheng-Po Yuan"'
Publikováno v:
Journal of the Formosan Medical Association, Vol 118, Iss 3, Pp 664-670 (2019)
Background/purpose: Recurrent aphthous stomatitis (RAS) is common and associated with certain comorbidities. The aim of this study was to investigate the prevalence of selected comorbidities in patients with RAUs and to compare the risks of comorbidi
Externí odkaz:
https://doaj.org/article/9d1ca01fc493446da79b360084910db6
Autor:
Hsin-Hsien Yu, Edward Chengchuan KO, Chia-Lun Chang, Kevin Sheng-Po Yuan, Alexander T. H. Wu, Yan-Shen Shan, Szu-Yuan Wu
Publikováno v:
Marine Drugs, Vol 16, Iss 10, p 392 (2018)
Purpose: Radiotherapy is a crucial treatment approach for many types of cancer. Radiation pneumonitis (RP) is one of the major complications in chest irradiation. Fucoidan is a sulfated polysaccharide found mainly in various species of brown seaweed.
Externí odkaz:
https://doaj.org/article/c036a96531a846df82adf001d022ed6c
Autor:
Yu-Chun Yen, Kevin Sheng Po Yuan, Chia Lun Chang, Jiaqiang Zhang, Alexander T.H. Wu, Lei Qin, Szu Yuan Wu
Publikováno v:
Journal of Cancer
Objective: We conducted this propensity score (PS)-matched, nationwide, population-based cohort study to estimate the effects of adjuvant oral or intravenous (IV) fluoropyrimidine in patients with high-risk stage II or III colon adenocarcinoma. Desig
Publikováno v:
Journal of the Formosan Medical Association, Vol 118, Iss 3, Pp 664-670 (2019)
Background/purpose: Recurrent aphthous stomatitis (RAS) is common and associated with certain comorbidities. The aim of this study was to investigate the prevalence of selected comorbidities in patients with RAUs and to compare the risks of comorbidi
Publikováno v:
JAMA network open. 3(3)
There is currently no system to predict 90-day morality among patients with locally advanced head and neck squamous cell carcinoma (HNSCC) after the completion of concurrent chemoradiotherapy (CCRT).To validate the accuracy of a predictive scoring sy
Autor:
Yu-Chun Yen, Jyh Ming Chow, Chia Lun Chang, Wei Cheng Lin, Yin Chun Chang, Han Lin Hsu, Jer Hwa Chang, Kevin Sheng Po Yuan, Alexander T.H. Wu, Szu Yuan Wu
Publikováno v:
Radiotherapy and Oncology. 129:52-60
Purpose Large-scale, prospective, randomized studies of the efficacy of thoracic radiotherapy (RT) in patients with unresectable stage IIIB–IV epidermal growth factor receptor (EGFR)-mutant lung adenocarcinomas who received and responded to EGFR ty
Autor:
Tsung Ming Chen, Jyh Ming Chow, Kuan Chou Lin, Szu Yuan Wu, Kevin Sheng Po Yuan, Chia Lun Chang
Publikováno v:
Radiotherapy and Oncology. 129:23-29
Background No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent low-dose (LD) or high-dose (HD) cisplatin with radiotherapy on nasopharyngeal cancer (NPC). Thus,
Autor:
Kevin Sheng Po Yuan, Ben Chang Shia, Lei Qin, Win Ping Deng, Kuan Chou Lin, Szu Yuan Wu, Yi Wei Kao, Tsung Ming Chen, Yueh Lung Lin, Bou Yue Peng, Alexander T.H. Wu
Publikováno v:
Cancer Medicine
Background Recurrent aphthous stomatitis (RAS) is considered a prophase symptom in patients with specific cancers. This study assessed the association between RAS and subsequent onset of cancer based on a nationwide population‐based database in Tai
Autor:
Chia Lun Chang, Yi Fang Ding, Han Lin Hsu, Jer Hwa Chang, Wei Cheng Lin, Alexander T.H. Wu, Kevin Sheng Po Yuan, Shee-Uan Chen, Szu Yuan Wu, Jyh Ming Chow
Publikováno v:
Cancer. 123:3904-3915
BACKGROUND Few large, prospective, randomized studies have investigated the value and optimal application of neoadjuvant chemoradiotherapy followed by surgery (trimodality therapy) or definitive concurrent chemoradiotherapy (CCRT) for patients with t
Autor:
Chia Lun Chang, Alexander T.H. Wu, Kevin Sheng Po Yuan, Wei Cheng Lin, Jer Hwa Chang, Yin Chun Chang, Han Lin Hsu, Szu Yuan Wu, Jeng Fong Chiou, Yu-Chun Yen, Jyh Ming Chow
Publikováno v:
Cancer. 123:2043-2053
BACKGROUND Few large, prospective, randomized studies have investigated the effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma (TESCC) who receive definitive radiotherapy (RT) or concurrent chemoradiotherapy (